474 related articles for article (PubMed ID: 25331088)
1. Risk of coronary heart disease in patients with HIV infection.
Zanni MV; Schouten J; Grinspoon SK; Reiss P
Nat Rev Cardiol; 2014 Dec; 11(12):728-41. PubMed ID: 25331088
[TBL] [Abstract][Full Text] [Related]
2. HIV infection and coronary heart disease: an intersection of epidemics.
Triant VA
J Infect Dis; 2012 Jun; 205 Suppl 3(Suppl 3):S355-61. PubMed ID: 22577208
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries.
Lang S; Boccara F; Mary-Krause M; Cohen A
Arch Cardiovasc Dis; 2015 Mar; 108(3):206-15. PubMed ID: 25725995
[TBL] [Abstract][Full Text] [Related]
5. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
Klein D; Hurley LB; Quesenberry CP; Sidney S
J Acquir Immune Defic Syndr; 2002 Aug; 30(5):471-7. PubMed ID: 12154337
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of coronary heart disease in patients with human immunodeficiency virus.
Triant VA
Rev Cardiovasc Med; 2014; 15 Suppl 1(0 1):S1-8. PubMed ID: 24987859
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.
Bucher HC; Rickenbach M; Young J; Glass TR; Vallet Y; Bernasconi E; Cavassini M; Fux C; Schiffer V; Vernazza P; Weber R; Battegay M;
Antivir Ther; 2010; 15(1):31-40. PubMed ID: 20167989
[TBL] [Abstract][Full Text] [Related]
8. Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls.
van den Dries L; Claassen MAA; Groothuismink ZMA; van Gorp E; Boonstra A
Virology; 2017 Sep; 509():133-139. PubMed ID: 28644978
[TBL] [Abstract][Full Text] [Related]
9. Ten-year predicted coronary heart disease risk in HIV-infected men and women.
Kaplan RC; Kingsley LA; Sharrett AR; Li X; Lazar J; Tien PC; Mack WJ; Cohen MH; Jacobson L; Gange SJ
Clin Infect Dis; 2007 Oct; 45(8):1074-81. PubMed ID: 17879928
[TBL] [Abstract][Full Text] [Related]
10. HIV and coronary heart disease: time for a better understanding.
Boccara F; Lang S; Meuleman C; Ederhy S; Mary-Krause M; Costagliola D; Capeau J; Cohen A
J Am Coll Cardiol; 2013 Feb; 61(5):511-23. PubMed ID: 23369416
[TBL] [Abstract][Full Text] [Related]
11. HIV Infection and Myocardial Infarction.
Calza L
Curr HIV Res; 2016; 14(6):456-465. PubMed ID: 27492726
[TBL] [Abstract][Full Text] [Related]
12. Coronary heart disease in HIV-infected individuals.
Currier JS; Taylor A; Boyd F; Dezii CM; Kawabata H; Burtcel B; Maa JF; Hodder S
J Acquir Immune Defic Syndr; 2003 Aug; 33(4):506-12. PubMed ID: 12869840
[TBL] [Abstract][Full Text] [Related]
13. Improvements in antiretroviral therapy outcomes over calendar time.
Boyd MA
Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
[TBL] [Abstract][Full Text] [Related]
14. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?
Fichtenbaum CJ
Curr HIV/AIDS Rep; 2010 May; 7(2):92-8. PubMed ID: 20425563
[TBL] [Abstract][Full Text] [Related]
15. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
16. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons.
Lakey W; Yang LY; Yancy W; Chow SC; Hicks C
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):435-40. PubMed ID: 23072344
[TBL] [Abstract][Full Text] [Related]
17. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
[TBL] [Abstract][Full Text] [Related]
18. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
[TBL] [Abstract][Full Text] [Related]
19. Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy.
Peltenburg NC; Schoeman JC; Hou J; Mora F; Harms AC; Lowe SH; Bierau J; Bakker JA; Verbon A; Hankemeier T; Boonstra A
Sci Rep; 2018 Nov; 8(1):16947. PubMed ID: 30446683
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic restoration in HIV-infected individuals.
Kim JM; Han SH
Immunotherapy; 2011 Feb; 3(2):247-67. PubMed ID: 21322762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
